Key result
Obstructive sleep apnea affects up to ~79% of HFpEF patients and drives disease progression.
Why the study?
Although OSA is associated with HFpEF onset and progression, the exact pathophysiological mechanisms underlying OSA-related HFpEF remain poorly elucidated, and relevant systematic reviews are scarce.
This narrative review synthesizes the pathophysiological crosstalk—including chronic intermittent hypoxia, HIF-1α signaling, systemic inflammation, and shared obesity/metabolic substrates—and clinical correlations linking obstructive sleep apnea to the progression of HFpEF.
Answers are grounded in this paper and cite their sources.
May prompt OSA screening in HFpEF; leaves open whether treatment modifies progression.
Obstructive sleep apnea (OSA) is closely associated with and represents a potential biological contributor to the onset and progression of heart failure with preserved ejection fraction (HFpEF). Although abundant studies have clarified the associations of OSA with cardiovascular diseases including hypertension, coronary artery disease, arrhythmia and heart failure with reduced ejection fraction (HFrEF), the exact pathophysiological mechanisms underlying OSA-related HFpEF remain poorly elucidated, and relevant systematic reviews are still scarce. This review summarizes the pathophysiological links and clinical correlations between OSA and HFpEF. Beyond classical mechanisms such as intrathoracic pressure swings and sympathetic overactivation, we highlight the pivotal roles of systemic inflammation, obesity, vascular injury and metabolic dysfunction in disease progression. We further elaborate how these interactive pathological pathways shape a clinically identifiable OSA–HFpEF phenotype, and summarize phenotype-based diagnostic strategies. Moreover, we discuss therapeutic implications for targeted management for patients with isolated OSA and comorbid OSA-HFpEF. Finally, we outline existing limitations and future research perspectives in the mechanistic exploration, diagnosis and management of OSA-HFpEF comorbidity.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) conducted a review in Obstructive sleep apnea (OSA) and heart failure with preserved ejection fraction (HFpEF). Obstructive sleep apnea (OSA) was evaluated. Obstructive sleep apnea has a 37%-79% prevalence in HFpEF cohorts and promotes disease progression via chronic intermittent hypoxia, HIF-1α signaling, systemic inflammation, and metabolic dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: